Hypothesis

Age-related senescence of choroid plexus epithelial cells (CPECs) initiates a localized senescence-associated secretory phenotype (SASP) that suppresses secreted α-Klotho transcription before measurable declines in circulating Klotho or rises in FGF23. This early brain‑specific Klotho loss disrupts cerebrospinal fluid (CSF) Klotho‑FGF23 signaling, leading to central FGF23 resistance that subsequently drives systemic phosphate dysregulation and multi‑organ aging.

Mechanistic Rationale

1. CPEC Senescence and SASP – CPECs exhibit heightened p16^INK4a^ and γH2AX signaling with age, secreting IL‑6, IL-1β, and TGF‑β1 (8). SASP factors are known to inhibit Klotho promoter activity via SMAD3‑dependent repression and NF‑κB‑mediated chromatin remodeling (3).
2. CSF Klotho as a Gatekeeper – Secreted Klotho in CSF acts as a high‑affinity FGF23 co‑factor that modulates FGFR1 signaling in hypothalamic nuclei controlling renal phosphate handling (4). Loss of CSF Klotho reduces FGF23‑dependent ERK phosphorylation in these centers, creating a central resistance state that blunts phosphaturic responses despite normal or elevated FGF23.
3. Feed‑Forward Loop – Central FGF23 resistance elevates serum FGF23 as a compensatory attempt to promote phosphaturia, but peripheral Klotho deficiency (especially in kidney) prevents effective signaling, resulting in hyperphosphatemia, VEGF‑driven vascular calcification, and cardiac hypertrophy (1, 2).
4. Progenitor Impact – Reduced CSF Klotho diminishes paracrine support for ventricular‑zone neural progenitors, exacerbating mitochondrial DNA damage and impairing neurogenic niches, which parallels the progenitor exhaustion seen in muscle and kidney (4).

Testable Predictions

• Prediction 1: In aged mice, CPEC-specific p16^INK4a^ positivity will correlate with decreased Klotho mRNA in choroid plexus tissue before a significant drop in plasma Klotho or rise in serum FGF23 (detectable at 12 months vs. 18 months).
• Prediction 2: Genetic ablation of senescence in CPECs (using p16‑3MR-driven ganciclovir) will preserve CSF Klotho levels, normalize hypothalamic FGFR1‑ERK signaling, and prevent the age‑dependent rise in serum FGF23 and hyperphosphatemia.
• Prediction 3: Pharmacological senolysis (navitoclax) administered to middle‑aged mice will rescue CSF Klotho, improve FGF23‑dependent phosphaturia, and attenuate vascular calcification compared with vehicle controls.
• Prediction 4: Intrathecal Klotho supplementation in senescent CPEC‑ablated mice will not further lower serum FGF23, indicating that the effect is mediated through restoration of the brain‑KL‑FGF23 axis rather than peripheral Klotho alone.

Falsifiability

If CPEC senescence does not precede systemic Klotho/FGF23 alterations—i.e., plasma Klotho declines or FGF23 rises without detectable changes in CPEC p16 expression or CSF Klotho—the hypothesis is refuted. Likewise, if senolysis of CPECs fails to preserve CSF Klotho or normalize FGF23 signaling despite effective reduction of p16^+^ cells, the proposed causal link is invalid.

Experimental Approach

• Use longitudinal MRI‑guarded choroid plexus microdissection in young (3 mo), middle‑aged (12 mo), and aged (24 mo) mice to quantify p16^INK4a^, Klotho mRNA, and CSF Klotho by ELISA.
• Cross p16‑3MR mice with CPEC‑specific Cre lines (Ttr‑Cre) to induce senolysis; measure serum FGF23, phosphate, Klotho, and markers of vascular calcification (Von Kossa) at intervals.
• Assess hypothalamic FGFR1‑ERK phosphorylation via Western blot of microdissected paraventricular nucleus.
• Conduct rescue experiments with intrathecal Klotho (1 µg) in senolysis‑treated animals to test for ceiling effects.

This framework integrates brain‑centric senescence with the systemic Klotho‑FGF23 axis, offering a precise, falsifiable mechanism that explains the temporal discordance between Klotho loss and FGF23 elevation observed across CKD and aging models.